Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in people who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them and their cancer.


Clinical Trial Description

The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in patients who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them and their cancer.

In the recurrent ovarian clear cell cancer (OCCC) setting, responses to further lines of chemotherapy are uniformly low. Given the limited benefit observed from chemotherapy treatments, there is now great interest in the development of molecular targeted therapy for the treatment of OCCC, including immunotherapy.

Researchers have found that sometimes the body's own immune system may be able to slow down or control cancer growth. Sometimes though, this natural immune system response stops, and the cancer cells are not killed by the immune system. Research has shown that in some patients, proteins on the surface of cancer cells and immune cells bind together and send signals that stop the immune cells from killing the cancer cells. One such protein is called Programmed Cell Death Ligand 1 or PD-L1 for short. New drugs like durvalumab work to block this signal and to increase the immune response against cancer cells. Durvalumab is an antibody to PDL1 (a protein that binds to PD1 and blocks the anti tumour activity of immune cells), and it is hoped that by blocking the interaction between PDL1 and PD1, the immune cells will once again be able to attack the cancer cells and thus prevent or slow down cancer growth.

This will be the first study to evaluate the efficacy of durvalumab in patients with recurrent ovarian clear cell carcinomas. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03405454
Study type Interventional
Source National University Hospital, Singapore
Contact David SP Tan
Phone (65) 6779 5555
Email david_sp_tan@nuhs.edu.sg
Status Recruiting
Phase Phase 2
Start date October 9, 2017
Completion date March 15, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05296512 - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Phase 2
Completed NCT01914510 - A Study of ENMD-2076 in Ovarian Clear Cell Cancers Phase 2
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Not yet recruiting NCT05600998 - A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma N/A
Recruiting NCT06065462 - Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Phase 1/Phase 2
Recruiting NCT05099978 - Asian Multicenter Prospective Study of ctDNA Sequencing
Not yet recruiting NCT05759312 - Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Phase 1/Phase 2
Not yet recruiting NCT06279104 - A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Recruiting NCT05498597 - AMT-151 in Patients With Selected Advanced Solid Tumours Phase 1
Recruiting NCT05226507 - A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer Phase 1
Recruiting NCT05281471 - Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Phase 3
Recruiting NCT04735861 - Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma Phase 2
Recruiting NCT02866370 - Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Phase 2